Hnub Nyoog Txog NAFLD: Kev Siv Cov Probiotics Ua Kev Pab Txhawb Kev Kho Mob Ntu 3
Jun 26, 2023
8. Lwm Txoj Kev Kho Mob
Raws li kev tshaj tawm dav dav, GM kev hloov kho sawv cev rau txoj hauv kev siv tau los tswj ntau yam kab mob, suav nrog NAFLD. Ntxiv rau probiotics, prebiotics, symbiotics, thiab lub npe hu ua fecal microbiota transplant (FMT) sawv cev rau lwm txoj kev siv los kho dysbiosis [188,189].
Glycoside ntawm cistanche tuaj yeem ua rau muaj kev ua haujlwm ntawm SOD hauv plawv thiab daim siab cov ntaub so ntswg, thiab txo cov ntsiab lus ntawm lipofuscin thiab MDA hauv txhua cov ntaub so ntswg, tshem tawm ntau yam reactive oxygen radicals (OH-, H₂O₂, thiab lwm yam) thiab tiv thaiv DNA puas. los ntawm OH-radicals. Cistanche phenylethanoid glycosides muaj peev xwm tshem tawm cov dawb radicals, muaj peev xwm txo tau ntau dua li cov vitamin C, txhim kho cov haujlwm ntawm SOD hauv cov phev ncua, txo cov ntsiab lus ntawm MDA, thiab muaj qee yam kev tiv thaiv ntawm cov phev ua haujlwm. Cistanche polysaccharides tuaj yeem txhim kho kev ua haujlwm ntawm SOD thiab GSH-Px hauv erythrocytes thiab ntsws cov ntaub so ntswg ntawm cov nas senescent sim los ntawm D-galactose, nrog rau txo cov ntsiab lus ntawm MDA thiab collagen hauv lub ntsws thiab ntshav, thiab nce cov ntsiab lus ntawm elastin, muaj Cov nyhuv scavenging zoo ntawm DPPH, ncua lub sijhawm ntawm hypoxia hauv cov nas senescent, txhim kho cov haujlwm ntawm SOD hauv cov ntshav, thiab ncua lub physiological degeneration ntawm lub ntsws hauv kev sim cov nas nrog cellular morphological degeneration, kev sim tau pom tias Cistanche muaj peev xwm antioxidant zoo. thiab muaj peev xwm los ua ib qho tshuaj tiv thaiv thiab kho cov kab mob ntawm daim tawv nqaij laus. Nyob rau tib lub sijhawm, echinacoside hauv Cistanche muaj lub peev xwm tseem ceeb los tshem tawm DPPH dawb radicals thiab tuaj yeem tshem tawm cov pa oxygen reactive, tiv thaiv dawb radical-induced collagen degradation, thiab kuj muaj kev kho zoo ntawm thymine dawb radical anion puas.
Nyem rau rou cong rong cov txiaj ntsig
【Yog xav paub ntxiv:george.deng@wecistanche.com / WhatApp:86 13632399501 】
Prebiotics yog "cov khoom xyaw uas tsis yog digestible uas muaj txiaj ntsig zoo rau tus tswv tsev noj qab haus huv, los ntawm kev xaiv kev txhawb nqa kev loj hlob thiab / lossis kev ua haujlwm ntawm cov kab mob muaj txiaj ntsig hauv plab hnyuv" [190]. Feem ntau ntawm lawv yog cov fibers uas tsis yog digestible, xws li fructooligosaccharides (FOS), galactooligosaccharides (GOS), lactulose, inulin, thiab pectin [191]. Lawv tuaj yeem tiv thaiv kab mob raws plab, nrog rau mob qog noj ntshav, hloov kho cov metabolism hauv plab hnyuv, txhawb cov ntxhia adsorption, thiab muaj cov txiaj ntsig zoo ntawm cov metabolism hauv lipid thiab immunomodulatory zog [192]. Tsis tas li ntawd, prebiotics tuaj yeem hloov kho qhov sib xyaw ntawm GM, los ntawm kev txhawb nqa kev loj hlob ntawm cov kab mob uas muaj txiaj ntsig zoo thiab txo cov kab mob Gram-negative [193-195]. Qee cov pov thawj tau pom tias kev noj tshuaj prebiotic tuaj yeem tiv thaiv NAFLD kev loj hlob thiab kev loj hlob [196,197]. Cov kev tshawb fawb qhia tias prebiotic fructo-oligosaccharides rov zoo li qub plab hnyuv microflora thiab plab hnyuv epithelial barrier muaj nuj nqi, thiab txo qis steatohepatitis hauv NASH qauv nas, thaum lactulose txhim kho hepatic o thiab txo qis ALT thiab AST cov ntshav hauv NASH qauv nas [198. Tsis tas li ntawd, ib qho randomized, ob-dig muag, placebo-tswj tshuaj ntsuam xyuas tau tshaj tawm tias Chlorella vulgaris tuaj yeem txo cov piam thaj hauv cov ntshav thiab txhim kho daim siab ua haujlwm thiab lipid profile hauv cov neeg mob NAFLD [200]; Ntxiv mus, hauv tib kab, Javadi (2017) tau pom tias prebiotic inulin txo qis AST thiab ALT, piv rau cov placebo. Txawm li cas los xij, lawv pom tsis muaj kev hloov pauv tseem ceeb hauv qib ntawm daim siab rog [201]. Thaum kawg, kev tswj hwm ntawm oligofructose txo qis ALT, AST, thiab insulin ntshav hauv cov neeg mob NASH [197]. Qhov zoo siab, qee qhov kev tshawb fawb qhia txog qhov cuam tshuam ntawm prebiotics ntawm GM hauv cov neeg laus [202-204]. Ob qhov randomized, ob-dig muag, kev tshuaj ntsuam xyuas placebo qhia tau hais tias galactooligosaccharides sib xyaw (B-GOS) nce cov kab mob uas muaj txiaj ntsig, tshwj xeeb tshaj yog Bifidobacteria [202,203], nrog rau GOS supplementation [204].
Symbiotics yog kev sib xyaw ua ke ntawm probiotics thiab prebiotics, qhov twg prebiotics nyiam kev loj hlob ntawm cov kab mob noj qab haus huv probiotics, yog li tsim kom muaj txiaj ntsig zoo hauv plab hnyuv, ua rau muaj txiaj ntsig zoo rau tus tswv tsev noj qab haus huv [188,192]. Symbiotics yuav tsum tau tsim los ntawm kev xaiv qhov tsim nyog ua ke ntawm probiotics thiab prebiotics, los txhawb txoj kev loj hlob thiab ciaj sia ntawm probiotics hauv plab hnyuv. Tsis tas li ntawd, cov mis symbiotic yuav tsum muaj txiaj ntsig zoo dua piv rau cov haujlwm ntawm tus kheej cov khoom [205]. Qee cov kev tshawb fawb qhia txog cov txiaj ntsig zoo ntawm symbiotic supplementation ntawm biochemical thiab histological nta ntawm NAFLD [206-212]. Malaguarnera et al. pom tias kev sib xyaw ua ke ntawm B. longum thiab FOS, ua ke nrog kev hloov pauv hauv kev ua neej, txo qis AST, TNF, thiab C-reactive protein (CRP) qib, HOMA index thiab serum endotoxin, nrog rau txo qhov mob thiab steatosis, hauv 66 NASH cov neeg mob [ 206]; Tsis tas li ntawd, ib qho kev soj ntsuam randomized, ob-dig muag, tshuaj placebo-tswj tau pom tias kev ntxiv ntawm xya probiotic hom (L. casei, L. rhamnosus, S. thermophilus, B. breve, L. acidophilus, B. longum, thiab L. bulgaricus. ) thiab FOS txo qis lub siab enzymes (ALT, AST, thiab GGT), thiab cov cim inflammatory (TNF, CRP, thiab tag nrho cov teeb meem nuclear kB p65) hauv 52 cov neeg mob nrog NAFLD [207]. Lwm qhov randomized, ob-dig muag, tshuaj placebo-tswj tshuaj ntsuam xyuas tau tshaj tawm tias kev sib xyaw ntawm kev noj haus fiber ntau thiab L. reuteri txo cov fibrosis, hepatic steatosis, thiab cov qib ntshav ntawm cov cim inflammatory hauv 50 cov neeg mob lean nrog NAFLD [208]. Thaum kawg, hauv kev sim tshuaj tsis ntev los no (kev tshawb fawb INSYTE), Scorletti (2020). pom tias Bifidobacterium animalis subsp. lactis BB-12 thiab FOS hloov cov fecal microbiome, tab sis tsis txhob txo cov rog hauv siab thiab cov cim ntawm daim siab fibrosis [209]. Symbiotics tuaj yeem hloov kho GM ntawm cov neeg laus [213–215]. Ob qhov muag tsis pom kev, kev sim tshuaj placebo-tswj qhia tias kev sib xyaw ntawm Bifidobacterium bifidum BB-02, Bifidobacterium lactis BL-01, thiab inulin, nrog rau kev sib xyaw ntawm Lactobacillus acidophilus NCFM thiab lactitol, tuaj yeem nce ntxiv. kev loj hlob ntawm Bifidobacteria thiab Lactobacilli [213,215]; Tsis tas li ntawd, lwm qhov kev sim tshuaj qhia tau hais tias kev sib xyaw ntawm Bifidobacterium longum thiab inulin nce tus naj npawb ntawm Actinobacteria thiab Firmicutes, thiab txo qis Proteobacteria [214]. Interestingly, Marìa Juàrez-Fernàndez li al. pom cov txiaj ntsig zoo ntawm kev sib xyaw ua ke ntawm NGP A. muciniphila thiab quercetin ntawm NAFLD, los ntawm kev hloov kho GM muaj pes tsawg leeg thiab cov kua tsib acid metabolism [216].
Fecal microbiota hloov pauv (FMT) yog cov txheej txheem uas cov khoom siv fecal los ntawm cov neeg noj qab haus huv tau muab tso rau hauv cov hnyuv ntawm cov neeg mob uas hloov GM, kom rov qab mus rau lub xeev ruaj khov thiab yog li kho cov kab mob tshwj xeeb ntsig txog dysbiosis [217]. Tam sim no, FMT tau siv tau zoo rau cov neeg mob uas muaj tus kab mob Clostridium difficile rov tshwm sim, metabolic syndrome, mob plab plob tsis so tswj, thiab rog [218], thiab tuaj yeem dhau los ua txoj kev kho mob zoo rau kev kho NAFLD. Nws tau pom tias kev kho kom zoo ntawm GM nrog FMT kev kho mob alleviated steatohepatitis hauv HFD qauv nas [219], thiab rov qab kho portal hypertension, insulin tsis kam, thiab endothelial dysfunction hauv NASH qauv nas [220]. Txog niaj hnub no, kev tshawb fawb tib neeg tsawg tau ua tiav, thiab tsis yog txhua tus tau pom cov txiaj ntsig zoo ntawm FMT hauv kev kho NAFLD. Piv txwv li, ob qhov muag tsis pom kev, randomized, tswj cov pov thawj ntawm txoj kev tshawb fawb qhia tias allogenic pub FMT nyob rau hauv cov neeg uas muaj hepatic steatosis ua rau muaj txiaj ntsig kev hloov pauv hauv cov kab mob siab hepatic thiab cov metabolites koom nrog hauv o thiab lipid metabolism [221]; Tsis tas li ntawd, lwm qhov randomized, tswj kev sim qhia tau hais tias allogenic FMT nyob rau hauv cov neeg mob nrog NAFLD tuaj yeem txo cov plab hnyuv permeability, tab sis tsis txhim kho cov tshuaj insulin tsis kam lossis txo cov rog hauv siab [222].
9. Cov lus xaus
NAFLD yog ib hom kab mob siab heev, tshwj xeeb tshaj yog thoob plaws hauv cov neeg laus uas muaj cov kab mob metabolic, uas yog tus cwj pwm los ntawm cov rog ntau dhau hauv hepatocytes. Ntau cov kev tshawb fawb sim ua ob qho tib si hauv cov tsiaj muaj hnub nyoog, (nyob rau hauv uas cov tsos mob ntawm tus kab mob no raug ntxias los ntawm cov rog rog thiab MCD noj) thiab hauv cov neeg laus nrog NAFLD, tau hais txog qhov muaj qhov hloov pauv GM, piv rau qhov pom hauv cov neeg noj qab nyob zoo. Hauv cov neeg laus, GM yog tus cwj pwm los ntawm qhov tshwj xeeb microbial kos npe (nce hauv Gram-tsis zoo cov kab mob thiab cov kab mob pathobionts, nrog rau qhov tso tawm ntawm endotoxins thiab LPS, thiab txo qis hauv Gram-positive microorganisms), thiab qhov hloov GM no zoo li ua si cuam tshuam. Lub luag haujlwm hauv kev txhawb nqa cov kab mob ntawm NAFLD. Lub plab hnyuv dysbiosis, nrog rau qib siab OS, txiav txim siab qhov nce hauv plab hnyuv permeability nrog rau qhov tso tawm ntawm ROS, endotoxins, thiab LPS rau hauv cov hlab ntsha. Ua ke, cov xwm txheej no ua rau muaj kev cuam tshuam ntau ntxiv los tsim tus kab mob thiab nyiam nws txoj kev loj hlob mus rau NASH. Yog li ntawd, raws li ntau qhov kev sim thiab kev sim tshuaj ntsuam xyuas, kev kho dua tshiab ntawm GM hloov mus rau lub xeev noj qab haus huv tuaj yeem yog riam phom tshiab los tswj NAFLD. Probiotics supplementation, ib leeg lossis ua ke nrog NAFLD cov kev kho mob ib txwm muaj, tuaj yeem sawv cev rau txoj hauv kev kho tshiab uas muaj peev xwm rov ua kom lub plab zom mov zoo, txawm tias lawv qhov kev sib koom ua ke tseem tsis tau paub zoo. Tseeb tiag, txawm hais tias probiotics tau siv ntau xyoo los tiv thaiv lossis kho qee yam kab mob, txog niaj hnub no, lawv cov txiaj ntsig hauv kev tawm tsam lossis txo NAFLD tseem tsis tau tshawb pom tag nrho. Txawm hais tias muaj kev vam meej, ob qho tib si kev tshawb fawb preclinical thiab randomized tswj kev sim tseem muaj tsawg los ua kom pom kev kho tau zoo hauv kev tswj hwm NAFLD. Ntxiv mus, yuav tsum muaj kev tshawb fawb ntau ntxiv, ntawm ib sab, kom paub meej lub luag haujlwm meej ntawm GM hloov pauv hauv cov kab mob ntawm cov kab mob siab, thiab lwm yam, txhawm rau nrhiav cov kab mob probiotic zoo tshaj plaws uas siv tau, ntau npaum li cas. muab tshuaj, thiab lub sijhawm ntawm kev kho mob.
Cov ntaub ntawv
1. de Vos, WM; Tug, H.; Van Hul, M.; Cani, PD Gut Microbiome thiab Kev Noj Qab Haus Huv: Mechanistic Insights. Xyoo 2022, 71, 1020–1032. [CrossRef] [PubMed]
2. Wu, H.-J.; Wu, E. Lub luag haujlwm ntawm Gut Microbiota hauv Immune Homeostasis thiab Autoimmunity. Gut Microbes 2012, 3, 4–14. [CrossRef] [PubMed] 3. Chen, Y.; Zhou, J.; Wang, L. Role thiab Mechanism of Gut Microbiota in Human Disease. Pem hauv ntej. Cell. Kab mob. Microbiol. 2021, 11, 625913. [CrossRef] [PubMed]
4. MacNee, W.; Rabinovich, RA; Choudhury, G. Kev laus thiab Ciam teb ntawm Kev Noj Qab Haus Huv thiab Kab Mob. Eur. Ua pa. J. 2014, 44, 1332–1352. [CrossRef]
5. Stahl, EC; Haschak, MJ; Popovic, IB; Brown, BN Macrophages nyob rau hauv Aging Liver thiab Age-Related Liver Disease. Pem hauv ntej. Immunol. 2018, 9, 2795. [CrossRef]
6. Papatheodoridi, A.; Chrysavgis, L.; Koutsilieris, M.; Chatzigeorgiou, A. Lub luag hauj lwm ntawm Senescence nyob rau hauv txoj kev loj hlob ntawm Nonalcoholic Fatty Liver Disease thiab Progression rau Nonalcoholic Steatohepatitis. Hepatology 2020, 71, 363–374. [CrossRef]
7. Gonzalez, A.; Huerta-Salgado, C.; Orozco-Aguilar, J.; Aguirre, F.; ib. Taus, F.; Ximoos, F.; Cabello-Verrugio, C. Lub luag hauj lwm ntawm Oxidative Stress nyob rau hauv Hepatic thiab Extrahepatic Dysfunctions thaum Nonalcoholic Fatty Liver Disease (NAFLD). Oxidative Med. Cell. Longev. Xyoo 2020, 1-16. [CrossRef]
8. Jiang, X.; Zheng, J.; Zhang, S.; Wang, IB; Wu, C.; Guo, X. Kev nce qib hauv kev koom tes ntawm Gut Microbiota hauv Pathphysiology ntawm NAFLD. Pem hauv ntej. Med. 2020, 7, 361. [CrossRef]
9. Hrncir, T.; Hrncirova, L.; Kev, M.; Hromadka, R. Machova, V.; Trckova, E.; Kostovcikova, K. Kralickova, P. Krejsek, J.; Tlaskalova-Hogenova, H. Gut Microbiota thiab NAFLD: Pathogenetic Mechanisms, Microbiota Kos npe, thiab kev kho mob. Microorganisms 2021, 9, 957. [CrossRef]
10. Arab, JP; Arrese, M.; ib. Trauner, M. Kev nkag siab tsis ntev los no rau hauv Pathogenesis ntawm Nonalcoholic Fatty Liver Disease. Annu. Rev. Pathol. Mech. Dis. 2018, 13, 321–350. [CrossRef]
11. Buzzetti, E.; Pinzani, M.; Tsochatzis, EA Qhov Ntau-Hit Pathogenesis ntawm Non-Alcoholic Fatty Liver Disease (NAFLD). Metabolism 2016, 65, 1038–1048. [CrossRef] [PubMed]
12. Lin, W.-Y.; Lin, J.-H.; Kuo, Y.-W.; Chiang, P.-FR; Ho, H.-H. Probiotics thiab lawv cov metabolite txo qis Oxidative Stress nyob rau nruab nrab cov nas. Curr. Microbiol. 2022, 79, 104. [CrossRef] [PubMed]
13. Di Pasqua, LG; Cagna, M.; Berardo, C.; ib. Vairetti, M.; ib. Ferrigno, A. Cov Ntsiab Lus Qhia Txog Molecular Kev Koom Tes Hauv Kev Siv Tshuaj Txhaum Cai Tsis Muaj Cawv Tsis Muaj Dej Cawv Ntshav Qab Zib thiab Tsis-Alcoholic Steatohepatitis: Kev Hloov Kho. Biomedicines 2022, 10, 194. [CrossRef] [PubMed]
14. Berardo, C.; Di Pasqua, LG; Cagna, M.; Richelmi, P.; Vairetti, M.; ib. Ferrigno, A. Nonalcoholic Fatty Liver Disease thiab Nonalcoholic Steatohepatitis: Cov teeb meem tam sim no thiab cov kev xav yav tom ntej hauv Preclinical thiab Clinical Research. Int. J. Mol. Sci. 2020, 21, 9646. [CrossRef]
15. Younossi, ZM; Rinella, ME; Sanyal, AJ; Harrison, SA; Brunt, EM; Goodman, Z.; Cohen, DE; Loomba, R. Los ntawm NAFLD rau MAFLD: Qhov cuam tshuam ntawm kev hloov ntxov ntxov hauv cov lus siv. Hepatology 2021, 73, 1194–1198. [CrossRef]
16. Younossi, ZM; Koenig, AB; Abdelatif, D.; Fazel, Y.; Henry, L.; Wymer, M. Ntiaj teb no kev kis mob ntawm Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incident, and Outcomes. Hepatology 2016, 64, 73–84. [CrossRef]
17. Jinjuvadia, R.; Antaki, F.; Lohia, P.; Liangpunsakul, S. Lub koom haum ntawm Nonalcoholic Fatty Liver Disease thiab Metabolic Abnormalities hauv Tebchaws Meskas Cov Neeg. J. Clin. Gastroenterol. 2017, 51, 160–166. [CrossRef]
18. Younossi, ZM; Golabi, P.; de Avila, L.; ib. Paik, JM; Srishord, M. Fukui, N.; Qiu, Y.; Kub, L.; Afendy, UA; Nader, F. Lub Ntiaj Teb Kev Kab Mob Sib Kis ntawm NAFLD thiab NASH hauv Cov Neeg Mob Ntshav Qab Zib Hom 2: Kev Ntsuam Xyuas Txheej Txheem thiab Meta-Tshawb. J. Hepatol. Xyoo 2019, 71, 793–801. [CrossRef]
19. Ferrigno, A.; Berardo, C.; ib. Di Pasqua, LG; Cagna, M.; Siciliano, V.; Richelmi, P.; Vairetti, M. Kev Xaiv Thaiv ntawm Metabotropic Glutamate Receptor-5 Attenuates Fat Accumulation nyob rau hauv Vitro Model ntawm Benign Steatosis. Eur. J. Histochem. 2020, 64, 3175. [CrossRef]
20. Peverill, W.; Powell, LW; Skoien, R. Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation. Int. J. Mol. Sci. Xyoo 2014, 15, 8591–8638. [CrossRef]
21. Hnub, CP; Saksena, S. Non-Alcoholic Steatohepatitis: Txhais thiab Pathogenesis. J. Gastroenterol. Hepatol. 2002, 17, S377–S384. [CrossRef] [PubMed]
22. Hebbard, L.; George, J. Tsiaj qauv ntawm Nonalcoholic Fatty Liver Disease. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 35–44. [CrossRef] [PubMed]
23. Guilherme, A.; Virbasius, JV; Puri, V.; Czech, MP Adipocyte Dysfunctions Linking Obesity to Insulin Resistance and Type 2 Diabetes. Nat. Rev. Mol. Cell Bio. Xyoo 2008, 9, 367–377. [CrossRef] [PubMed]
24. Gong, Z.; Tas, E.; Yakar, S.; Muzumdar, R. Hepatic Lipid Metabolism thiab Non-Alcoholic Fatty Liver Disease in Aging. Mol. Cell. Endocrinol. 2017, 455, 115–130. [CrossRef]
25. Barzilai, N.; Huffman, DM; ib. Muzumdar, RH; Bartke, A. Lub luag haujlwm tseem ceeb ntawm Metabolic Pathways hauv Kev Laus. Ntshav Qab Zib 2012, 61, 1315–1322. [CrossRef]
26. Puab, C.; Girard, J. Kev koom tes ntawm de Novo Fatty Acid Synthesis rau Hepatic Steatosis thiab Insulin Resistance: Lessons from Genetically Engineered nas. J. Clin. Tshawb xyuas. 2008, 118, 829–838. [CrossRef]
27. Xu, X.; Yog li, J.-S.; Park, J.-G.; Li, A.-H. Transcriptional Control ntawm Hepatic Lipid Metabolism los ntawm SREBP thiab ChREBP. Semin. Lub siab Dis. 2013, 33, 301–311. [CrossRef]
28. Gruzdeva, O.; Borodkina, D.; Uchasova, E.; Dyleva, Y.; Barbarash, O. Leptin Resistance: Cov Mechanisms thiab Diagnosis. Diabetes Metab. Syndr. Obes. 2019, 12, 191–198. [CrossRef]
29. Mendoza-Herrera, K.; Florio, UA; Moore, M.; Marrero, UA; Tamez, M.; Bhupathiraju, SN; Mattei, J. Lub Leptin System thiab Kev Noj Qab Haus Huv: Kev Ntsuam Xyuas Mini ntawm Cov Ntaub Ntawv Tam Sim No. Pem hauv ntej. Endocrinol. 2021, 12, 749050. [CrossRef]
30. Margetic, S.; Gazzola, C.; Peb, G.; Hill, R. Leptin: Kev Ntsuam Xyuas Ntawm Nws Qhov Kev Ua Haujlwm thiab Kev Sib Raug Zoo. Int. J. Obes. 2002, 26, 1407–1433. [CrossRef]
31. Muoio, DM; Lynis Dohm, G. Peripheral Metabolic Actions of Leptin. Qhov Zoo Tshaj Plaws. Res. Clin. Endocrinol. Metab. 2002, 16, 653–666. [CrossRef]
32. Cusi, K. Lub luag haujlwm ntawm Insulin Resistance thiab Lipotoxicity hauv Non-Alcoholic Steatohepatitis. Clin. Lub siab Dis. Xyoo 2009, 13, 545–563. [CrossRef] [PubMed]
33. Yilmaz, Y. Saib Tshooj Lus: Puas Yog Kab Mob Ntshav Qab Zib Tsis Muaj Kab Mob Ntshav Qab Zib yog Kab Mob Ntshav Qab Zib, lossis Puas Yog Steatosis thiab Non-Alcoholic Steatohepatitis Cov Kab Mob Tsis Zoo? Khoom noj khoom haus. Pharmacol. Ther. 2012, 36, 815–823. [CrossRef]
34. Li, H.-Y.; Peng, Z.-G. Targeting lipophagy raws li ib tug muaj peev xwm kho lub tswv yim rau Nonalcoholic Fatty Liver Disease. Biochem. Pharmacol. 2022, 197, 114933. [CrossRef] [PubMed]
35. Carotti, S.; Aquilano, K.; Zalfa, F.; Ruggiero, S.; Valentini, F.; ib. Zingariello, M.; Francesconi, M.; ib. Perrone, G.; Alletto, F.; ib. AntonelliIncalzi, R.; ua al. Lipophagy Impairment yog txuam nrog Kab Mob Progression hauv NAFLD. Pem hauv ntej. Physiol. 2020, 11, 850. [CrossRef] [PubMed]
36. Grefhorst, A.; van de Peppel, IP; Larsen, LE; Jonker, JW; Holleboom, AG Lub luag haujlwm ntawm Lipophagy hauv Kev Txhim Kho thiab Kev Kho Mob Tsis Muaj Cawv Fatty Liver Disease. Pem hauv ntej. Endocrinol. 2021, 11, 601627. [CrossRef] [PubMed]
37. Cаtoi, AF; Corina, UA; Katsiki, N.; Vodnar, DC; Andreicut, , AD; Stoian, AP; Rizzo, M.; Pérez-Martínez, P. Gut Microbiota thiab Aging-A Focus on Centenarians. Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 2020, 1866, 165765. [CrossRef]
38. Lloyd-Price, J.; Abu-Ali, G.; Huttenhower, C. Kev Noj Qab Haus Huv Tib Neeg Microbiome. Genome Med. 2016, 8, 51. [CrossRef]
39. Juárez-Fernández, M.; Porras, D.; García-Mediavilla, MV; Roman-Sagüillo, S.; González-Gallego, J.; Nistal, E.; Sánchez-Campos, S. Aging, Gut Microbiota thiab Metabolic Diseases: Kev tswj los ntawm kev tawm dag zog lub cev thiab kev noj zaub mov zoo. Nutrients 2020, 13, 16. [CrossRef]
40. Marciano, F.; Vajro, P. Oxidative Stress, thiab Gut Microbiota. Nyob rau hauv cov ntaub so ntswg gastrointestinal; Elsevier: Amsterdam, Lub Netherlands, 2017; ib., 113–123. ISBN 978-0-12-805377-5.
41. Collado, MC; Rautava, S.; Aakko, J.; Isolauri, E.; Salminen, S. Human Gut Colonization Tej zaum yuav pib hauv Utero los ntawm Distinct Microbial Zej Zog hauv Placenta thiab Amniotic Fluid. Sci. Rep. 2016, 6, 23129. [CrossRef]
42. Mohajeri, MH; Brummer, RJM; Rastall, RA; Weersma, RK; Harmsen, HJM; Faas, M.; Eggersdorfer, M. Lub luag haujlwm ntawm Microbiome rau Tib Neeg Kev Noj Qab Haus Huv: Los ntawm Kev Tshawb Fawb Txog Kev Tshawb Fawb mus rau kev siv tshuaj kho mob. Eur J. Nutr. 2018, 57, 1–14. [CrossRef] [PubMed]
43. Claesson, MJ; Cusack, S.; O'Sullivan, UA; Greene-Diniz, R.; de Weerd, H.; Flannery, E.; Marchesi, JR; Falaus, D.; Dina, T.; Fitzgerald, G.; ua al. Kev sib xyaw, kev hloov pauv, thiab kev ruaj ntseg ntawm lub plab hnyuv microbiota ntawm cov neeg laus. Proc. Natl. Acad. Sci. USA 2011, 108, 4586–4591. [CrossRef]
44. Lozupon, CA; Stombaugh, JI; Gordon, IB; Jansson, JK; Knight, R. Diversity, Stability thiab Resilience of Human Gut Microbiota. Xwm Txheej 2012, 489, 220–230. [CrossRef]
45. Santoro, UA; Ostan, R.; Candela, M.; ib. Biagi, E.; Brigidi, P.; Kapri, M.; Franceschi, C. Gut Microbiota Hloov nyob rau hauv ntau xyoo caum ntawm tib neeg lub neej: Kev tsom mus rau Centenarians. Cell. Mol. Lub neej Sci. 2018, 75, 129–148. [CrossRef] [PubMed]
46. Dam, B.; Misra, A.; Banerjee, S. Lub luag hauj lwm ntawm Gut Microbiota nyob rau hauv Combating Oxidative Stress. Hauv Oxidative Stress nyob rau hauv cov kab mob microbial; Chakraborti, S., Chakraborti, T., Chattopadhyay, D., Shaha, C., Eds.; Springer: Singapore, 2019; Ib., 43–82.
47. Jasirwan, COM; Lesmana, CRA; Hasan, ib.; Sulaiman, AS; Gani, RA Lub luag hauj lwm ntawm Gut Microbiota nyob rau hauv Non-Alcoholic Fatty Liver Disease: Pathways of Mechanisms. Biosci. Microbiota Food Health 2019, 38, 81–88. [CrossRef] [PubMed]
48. Jones, RM; Mercante, JW; Neish, AS Reactive Oxygen Production Induced by the Gut Microbiota: Pharmacotherapeutic Implications. CMC 2012, 19, 1519–1529. [CrossRef]
49. Knights, D.; Parfrey, LW; Zaneveld, J.; ib. Lozupone, C.; Knight, R. Human-Associated Microbial Signatures: Kev tshuaj xyuas lawv tus nqi kwv yees. Cell Host Microbe 2011, 10, 292–296. [CrossRef]
50. Baumn, A.; Hernández-Arriaga, A.; Brandt, ib.; Sánchez, V.; Neeb, A.; Jung, F.; Kev, R.; Hoob, A.; Grune, T.; Fram, C.; ua al. Microbiota Profiling nyob rau hauv Aging-Associated Inflamation thiab Liver Degeneration. Int. J. Med. Microbiol. 2021, 311, 151500. [CrossRef]
51. Sharma, R. Emerging Interrelationship between the Gut Microbiome and Cellular Senescence in the Context of Aging and Disease: Kev Pom Zoo thiab Kev Kho Mob. Probiotics Antimicrob. Prot. 2022. [CrossRef]
52. García-Peña, C.; Álvarez-Cisneros, T.; Quiroz-Baez, R.; Friedland, RP Microbiota thiab Aging. Kev tshuaj xyuas thiab kev tawm tswv yim. Arch. Med. Res. Xyoo 2017, 48, 681–689. [CrossRef]
53. Kim, S.; Jazwinski, SM Lub plab Microbiota thiab Kev Noj Qab Haus Huv Kev Laus: Kev Ntsuam Xyuas Mini. Gerontology 2018, 64, 513–520. [CrossRef] [PubMed]
54. Khawm, A.; Ding, Z.; Ib, M.; Bacha, AS; Khan, ib.; Hanif, UA; Li, W. Guo, X. Nkag siab qhov cuam tshuam ntawm Gut Microbiota Dysbiosis ntawm Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Tsis ntev los no hloov tshiab. Int. J. Biol. Sci. 2021, 17, 818–833. [CrossRef] [PubMed] 55. Sivamaruthi, BS; Fern, LA; Rashidah Pg Hj Ismail, DSN; Chaiyasut, C. Qhov cuam tshuam ntawm Probiotics ntawm Bile Acids hauv Kab Mob thiab Kev Laus. Biomed. Kws tshuaj. 2020, 128, 110310. [CrossRef] [PubMed]
56. Salazar, N.; Arboleya, S.; Valdés, L.; Stanton, C.; ib. Rosas, P.; Rau, L.; Gueimonde, M.; de los Reyes-Gavilán, CG Tib neeg plab hnyuv microbiome ntawm Cov Hnub Nyoog Kawg ntawm Lub Neej. Dietary Intervention as a Way to Counteract Alterations. Pem hauv ntej. Genet. 2014, 5. [CrossRef]
57. Acharya, C.; Bajaj, JS Cov Kab Mob Siab Kab Mob Siab thiab Microbiome—Kev Txhais Peb Txoj Kev Paub ntawm Gut Microbiota rau Kev Tswj Xyuas Kab Mob Siab. Gastroenterology 2021, 160, 556–572. [CrossRef]
58. Alqahtani, SA; Schattenberg, JM NAFLD hauv Cov Neeg Laus. CIA 2021, 16, 1633–1649. [CrossRef]
59. Oudshoorn, C.; van der Cammen, TJM; McMurdo, MET; van Leeuwen, JPTM; Colin, EM Aging thiab Vitamin D Deficiency: Cov teebmeem ntawm Calcium Homeostasis thiab kev xav rau Vitamin D ntxiv. Br. J. Nutr. 2009, 101, 1597–1606. [CrossRef]
60. Riaz Rajoka, MS; Thirumdas, R.; Mehwish, HM; Umair, M.; Khurshid, M.; Hayat, HF; Phimolsiripol, Y.; Pallarés, N.; Martí- Quijal, FJ; Barba, FJ Lub luag haujlwm ntawm Cov Khoom Noj Antioxidants hauv Modulating Gut Microbial Zej Zog: Kev nkag siab tshiab hauv plab hnyuv Oxidative kev nyuaj siab thiab lawv cuam tshuam rau Kev Noj Qab Haus Huv. Antioxidants 2021, 10, 1563. [CrossRef]
61. Maier, L.; Pruteanu, M.; Koj, M.; Zeller, G.; Telzerow, A.; Anderson, EE; Brochado, UA; Fernandez, KC; Dos, H.; Mori, H.; ua al. Kev cuam tshuam ntau ntawm cov tshuaj tsis yog tshuaj tua kab mob rau tib neeg lub plab kab mob. Xwm Txheej 2018, 555, 623–628. [CrossRef]
62. Pascale, A.; Marchesi, N.; Govoni, S.; Barbieri, A. Targeting the Microbiota in Pharmacology of Psychiatric Disorders. Pharmacol. Res. 2020, 157, 104856. [CrossRef]
63. Santos, AL; Sinha, S.; Lindner, AB Qhov Zoo, Qhov Phem, thiab Dab Ntxaug ntawm ROS: Kev Pom Zoo Tshiab ntawm Kev Laus thiab Kev Laus Txog Kab Mob los ntawm Eukaryotic thiab Prokaryotic Model Organisms. Oxidative Med. Cell. Longev. Xyoo 2018, 1-23. [CrossRef] [PubMed]
64. Tan, BL; Norhaizan, ME; Liew, W.-P.-P.; Sulaiman Rahman, H. Antioxidant thiab Oxidative Stress: Ib qho kev sib koom ua ke hauv cov kab mob hnub nyoog. Pem hauv ntej. Pharmacol. 2018, 9, 1162. [CrossRef] [PubMed]
65. Conti, V.; Ib, V.; Corbi, G.; Russomanno, G.; Manzo, V.; De Lis, F.; Di Donato, A.; Filippelli, A. Antioxidant Supplementation nyob rau hauv kev kho mob ntawm Aging-Associated Diseases. Pem hauv ntej. Pharmacol. 2016, 7. [CrossRef] [PubMed]
66. Delli Bovi, AP; Marciano, F.; Mandato, C.; Siano, MA; Savia, M.; Vajro, P. Oxidative Stress in Non-Alcoholic Fatty Liver Disease. Ib qho Kev Ntsuam Xyuas Mini Hloov Kho Tshiab. Pem hauv ntej. Med. 2021, 8, 595371. [CrossRef] [PubMed]
67. Tsev, MC; Tansey, MG Lub plab-Brain Axis: Puas yog plab hnyuv plab yog tus tsav ntsiag to ntawm Parkinson's Disease Pathogenesis? npj Parkinson's Dis. 2017, 3, 3. [CrossRef]
68. Yardeni, T.; Tanes, CE; Kev, K.; Mattei, LM. Schaefer, PM; Singh, LN; Wu, GD; Murdock, DG; Wallace, DC Host Mitochondria Influence Gut Microbiome Diversity: Lub luag haujlwm rau ROS. Sci. Teeb liab. Peb Hlis 2019, 12, 3159. [CrossRef]
69. Derrien, M.; ib. Veiga, P. Rethinking Diet to Aid Human–Microbe Symbiosis. Trends Microbiol. 2017, 25, 100–112. [CrossRef]
70. Peng, C.; Stewart, AW; Woodman, OL; Ritchie, RH; Qin, CX Non-Alcoholic Steatohepatitis: Kev Ntsuam Xyuas ntawm Nws Cov Txheej Txheem, Cov Qauv thiab Kev Kho Mob. Pem hauv ntej. Pharmacol. 2020, 11, 603926. [CrossRef]
71. Gupta, H.; Min, B.-H.; Ganesan, R.; Gebru, YA; Sharma, SP; Park, E.; Won, S.-M.; Yim, J.-J.; Li, S.-B.; Cha, M.-G.; ua al. Gut Microbiome nyob rau hauv Non-Alcoholic Fatty Liver Disease: Los ntawm Mechanisms to Therapeutic Role. Biomedicines 2022, 10, 550. [CrossRef]
72. Aron-Wisnewssky, J.; Vigliotti, C.; Witjes, J.; Le, P.; Holleboom, AG; Verheij, J.; Nieuwdorp, M.; Clément, K. Gut Microbiota thiab Tib Neeg NAFLD: Disentangling Microbial Signatures los ntawm Metabolic Disorders. Nat. Rev. Gastroenterol. Hepatol. Xyoo 2020, 17, 279–297. [CrossRef]
73. Bäckhed, F.; ib. Ding, H.; Vang, T.; Hooper, LV; Gou, YK; Neeb, A.; Semenkovich, CF; Gordon, JI Lub plab Microbiota ua ib qho Environmental Factor uas tswj cov roj cia. Proc. Natl. Acad. Sci. USA 2004, 101, 15718. [CrossRef] [PubMed]
74. Bäckhed, F.; ib. Manchester, JK; Semenkovich, CF; Gordon, JI Los Ntawm Lub Npog: Mechanisms Hauv qab Qhov Kev Ua Phem Rau Kev Noj Qab Haus Huv-Induced Obesity nyob rau hauv cov nas tsis muaj kab mob. Proc. Natl. Acad. Sci. USA 2007, 104, 979. [CrossRef] [PubMed]
75. Kaden-Volynets, V.; Basic, M.; Neeb, U.; Pretz, D.; Nplhaib, A.; Bleich, A.; Bischoff, SC Tsis Muaj Lub Siab Steatosis hauv Cov Kab Mob Tsis Muaj Kab Mob Tom Qab Hypercaloric Diets. Eur. J. Nutr. Xyoo 2019, 58, 1933–1945. [CrossRef] [PubMed]
76. Sharpton, SR; Schnabl, IB; Knight, R.; Loomba, R. Cov Ntsiab Lus Tam Sim No, Lub Sijhawm, thiab Cov Teeb Meem ntawm Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. Cell Metab. 2021, 33, 21–32. [CrossRef]
77. Le Roy, T.; Llopis, M.; Lus, P.; Bruneau, UA; Raub, S.; Bevilacqua, C.; Martin, P.; Philippe, C.; Walker, F.; ib. Bado, UA; ua al. Cov hnyuv microbiota txiav txim siab kev txhim kho ntawm cov kab mob uas tsis yog-Alcoholic Fatty Liver Disease hauv nas. Xyoo 2013, 62, 1787–1794. [CrossRef]
78. Chiu, CC; Ching, YH; Li, YP; Liu, JY; Huang, YT; Huang, YW; Yang, SS; Huang, WC; Chuang, HL Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Nice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis. Nutrients 2017, 9, 1220. [CrossRef]
79. Porras, D.; Nistal, E.; Martínez-Flórez, S.; Olcoz, JL; Jover, R.; Jorquera, F. González-Gallego, J.; García-Mediavilla, MV; Sánchez-Campos, S. Kev Ua Haujlwm Kev Sib Raug Zoo ntawm Gut Microbiota Transplantation, Quercetin, thiab High-Fat Diet Txiav txim siab Tsis Muaj Cawv Fatty Liver Disease Development in Germ-Free nas. Mol. Nutr. Khoom noj khoom haus Res. 2019, 63. [CrossRef]
80. Schneider, KM; Bieg, V.; Heymann, F.; Hu, W.; Dreymueller, D.; Liao, L.; Frissen, M.; ib. Ludwig, A.; Gassler, N.; Pabst, O.; ua al. CX3CR1 yog tus neeg saib xyuas lub plab hnyuv siab rau hauv cov nas: txwv Steatohepatitis los ntawm kev tuav plab hnyuv Homeostasis. Hepatology 2015. [CrossRef]
81. Palladini, G.; Di Pasqua, LG; Berardo, C.; ib. Siciliano, V.; Richelmi, P.; Perlini, S.; ib. Ferrigno, UA; Vairetti, M. Tsiaj Models of Steatosis (NAFLD) thiab Steatohepatitis (NASH) Exhibit Hepatic Lobe-Specific Gelatinases Activity thiab Oxidative Stress. Ua tau. J. Gastroenterol. Hepatol. 2019, 2019. [CrossRef]
82. Yog, JZ; Li, YT; Wu, WR; Shi, D.; Fang, DQ; Yang, LY; Bian, XYA; Wu, JJ; Wang, Q.; Jiang, XW; ua al. Dynamic Alterations nyob rau hauv lub plab Microbiota thiab Metabolome thaum lub sij hawm kev loj hlob ntawm Methionine-Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis. Ntiaj teb J. Gastroenterol. 2018. [CrossRef]
83. Schneider, KM; Mos, A.; Kili, K.; Candels, LS; Elfers, C.; Bennek, E.; Ben Schneider, L. Heymann, F.; Gassler, N.; Penders, J.; ua al. Intestinal Microbiota tiv thaiv MCD Kev Noj Qab Haus Huv Induced Steatohepatitis. Int. J. Mol. Sci. 2019. [CrossRef] [PubMed]
84. Velayudham, A.; Dolganiuc, UA; Ellis, M.; Petrasek, J.; Kodys, K.; Mandrekar, P. Szabo, G. VSL#3 Probiotic Treatment Attenuates Fibrosis yam tsis muaj kev hloov pauv hauv Steatohepatitis hauv Kev Noj Qab Haus Huv Induced Nonalcoholic Steatohepatitis Model hauv nas. Hepatology 2009. [CrossRef]
85. Tig, H.; Adolph, TE; Moschen, AR Multiple Parallel Hits Hypothesis nyob rau hauv Nonalcoholic Fatty Liver Disease: Revisited Tom qab ib xyoo caum. Hepatology 2021, 73, 833–842. [CrossRef] [PubMed]
86. Sprus, A.; Kanuri, G.; Wagnerberger, S.; Haub, S.; Bischoff, SC; Bergheim, I. Tus Hu Xov Tooj Zoo li 4 Muaj Kev Koom Tes Hauv Kev Txhim Kho ntawm Fructose-Induced Hepatic Steatosis hauv nas. Hepatology 2009, 50, 1094–1104. [CrossRef] [PubMed]
87. Krenkel, O.; ib. Puengel, T.; Govaere, UA; Abdallah, AW; Mossanen, JC; Kohlhepp, M.; Liebelt, A.; Lefebvre, E.; Luedde, T.; Hellerbrand, C.; ua al. Kev Kho Mob Inhibition of Inflammatory Monocyte Recruitment Txo Steatohepatitis thiab Liver Fibrosis. Hepatology 2018. [CrossRef] [PubMed]
88. Schnabl, B. Linking plab hnyuv Homeostasis thiab kab mob siab. Curr. Opin. Gastroenterol. 2013, 29, 264–270. [CrossRef]
89. Henao-Mejia, J.; Elinav, E.; Jin, C.; Hao, L.; Mehal, WZ; Strowig, T.; Thais, CA; Kau, AL; Eisenbarth, SC; Jurczak, MJ; ua al. Inflammasome-Mediated Dysbiosis Regulates Progression of NAFLD thiab Obesity. Xwm 2012. [CrossRef]
90. Gil-Gómez, A.; Brescia, P. Rescigno, M.; Romero-Gómez, M. Gut-Liver Axis nyob rau hauv Nonalcoholic Fatty Liver Disease: Qhov cuam tshuam ntawm Metagenome, End Products, thiab Epithelial thiab Vascular Barriers. Semin. Lub siab Dis. 2021. [CrossRef]
91. Velázquez, KT; Enos, RT; Bader, JE; Sougiannis, AT; Carson, MAS; Chatzistamou, I.; Carson, JA; Nagarkatti, PS; Nagarkatti, M.; Murphy, EA Lub Sij Hawm Ntev-Fat-Nyob Noj Zaub Mov Txhawb Kev Noj Qab Haus Huv Tsis Muaj Cawv Fatty Liver Disease thiab Hloov Pauv Microbiota hauv nas. World J. Hepatol. Xyoo 2019, 11, 619–637. [CrossRef]
92. Gómez-Zorita, S.; Aguirre, L.; ib. Milton-Laskibar, I.; Fernández-Quintela, A.; Trepiana, J.; Kajaraville, N.; Mosqueda-Solís, A.; González, M. Portillo, MP Kev sib raug zoo ntawm kev hloov hauv Microbiota thiab daim siab Steatosis Induced los ntawm High-Fat Feeding-Kev Ntsuam Xyuas ntawm Cov Qauv Qiv. Nutrients 2019, 11, 2156. [CrossRef]
93. Turnbaugh, PJ; Li, RE; Mahowald, MA; Magrini, V.; Mardis, ER; Gordon, JI Ib Qhov Obesity-Associated Gut Microbiome nrog Ntxiv Peev Xwm rau Zog Sau. Xwm Txheej 2006, 444, 1027–1031. [CrossRef]
94. Zhou, L.; Baker, SS; Gill, C.; Li, W.; Alkhouri, R.; Baker, RD; Gill, SR Characterization of Gut Microbiomes in Nonalcoholic Steatohepatitis (NASH) Cov neeg mob: Kev sib txuas ntawm Endogenous Cawv thiab NASH. Hepatology 2013, 57, 601–609. [CrossRef] [PubMed]
95. Shen, F.; ib. Zheng, RD; Sun, XQ; Ding, WJ; Wang, XYA; Ntxuam, JG Gut Microbiota Dysbiosis nyob rau hauv cov neeg mob uas tsis yog-Alcoholic Fatty Liver Disease. Hepatobiliary pancreat. Dis. Int. HBPD INT 2017, 16, 375–381. [CrossRef]
96. Alferink, LJM; Radjabzadeh, D.; Erler, NWS; Vojinovic, D.; Medina-Gomez, C.; Uitterlinden, AG; de Knegt, RJ; Amin, N.; Ikram, MA; Janssen, HLA; ua al. Microbiomics, Metabolomics, Predicted Metagenomics, thiab Hepatic Steatosis nyob rau hauv Kev Tshawb Fawb Txog Pej Xeem ntawm 1,355 Cov Neeg Laus. Hepatology 2021, 73, 968–982. [CrossRef] [PubMed]
97. Del Chierico, F.; Nobili, V.; Vernocchi, P. Russo, UA; De Stefanis, C.; Neeb, D.; Furlanello, C.; Zandonà, UA; Paci, P.; Kauv, G.; ua al. Gut Microbiota Profiling ntawm Pediatric Nonalcoholic Fatty Liver Disease thiab Obese Patients Unveiled by an Integrated Meta-Omics-Based Approach. Hepatology 2017, 65, 451–464. [CrossRef]
98. Loomba, R.; Seguritan, V.; Li, W. Ntev, T.; Klitgord, N.; Bhatt, A.; Dulai, PS; Cais, C.; Bettencourt, R. Highlander, SK; ua al. Gut Microbiome-Based Metagenomic Signature rau Non-Invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017, 25, 1054–1062.e5. [CrossRef]
99. Vam, B.; Jiang, X.; Cai, M.; Ge, J.; Bao, Q.; Tang, L.; Chen, Y.; Li, L. Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-Alcoholic Fatty Liver Disease. Sci. Rep. 2016, 6, 1–11. [CrossRef]
100. Raman, M.; Ahmed, ib.; Gillevet, PM; Probert, NWS; Ratcliffe, NM; Smith, S.; Greenwood, R.; Sikaroodi, M.; Lam, V.; Crotty, P.; ua al. Fecal Microbiome thiab Volatile Organic Compound Metabolome nyob rau hauv cov tib neeg rog rog nrog Nonalcoholic Fatty Liver Disease. Clin. Gastroenterol. Hepatol. 2013, 11, 868–875.e3. [CrossRef]
101. Boursier, J.; Mueller, UA; Barret, M.; Machado, M.; Fizanne, L.; ib. Araujo-Perez, F.; Txiv neej, CD; Noob, PC; Raul, JF; David, LA; ua al. Qhov hnyav ntawm Nonalcoholic Fatty Liver Disease yog txuam nrog lub plab dysbiosis thiab ua haujlwm hauv kev ua haujlwm ntawm lub plab microbiota. Hepatology 2016, 63, 764–775. [CrossRef]
102. Morelli, L.; Capurso, L. FAO/WHO Cov Lus Qhia ntawm Probiotics: 10 Xyoo Tom Qab. J. Clin. Gastroenterol. 2012, 46, S1–S2. [CrossRef]
103. Gupta, V.; Garg, R. PROBIOTICS. Indian J. Med. Microbiol. 2009, 27, 202–209. [CrossRef] [PubMed]
104. Kumar, H.; Salminen, S. Probiotics. Hauv Encyclopedia of Food and Health; Elsevier: Amsterdam, Lub Netherlands, 2016; Ib., 510–515.
105. Aeron, G.; Morya, S. Probiotics as Therapeutics. JARB 2017, 2, 1–6. [CrossRef]
106. Thomas, CM; Versalovic, J. Probiotics-Host Communication: Modulation of Signaling Pathways in the hnyuv. Gut Microbes 2010, 1, 148–163. [CrossRef] [PubMed]
【Yog xav paub ntxiv:george.deng@wecistanche.com / WhatApp:86 13632399501 】
